Axiom Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

Axiom Investors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-77,772	Closed	-$42.2M	–	142
2015 Q4	$42.2M	Sell	77,772 -24,143	-24%	-$13.1M	1.36%	29
2015 Q3	$47.4M	Sell	101,915 -35	-0%	-$18.8K	1.5%	28
2015 Q2	$52M	Sell	101,950 -12,223	-11%	-$5.97M	1.49%	27
2015 Q1	$51.5M	Sell	114,173 -7,437	-6%	-$3.15M	1.39%	27
2014 Q4	$49.9M	Sell	121,610 -10,375	-8%	-$4.08M	1.23%	34
2014 Q3	$47.6M	Buy	+131,985	New	+$44.2M	1.18%	33

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Axiom Investors's REGN Position: Q1 2016 in Review

Axiom Investors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2016, closing a stake of 77,772 shares — an estimated $42.2M sold.

Axiom Investors first reported a position in REGN in Q3 2014 and held it in 6 quarters. The position peaked at $52M in Q2 2015. 550 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

Axiom Investors reported no remaining Regeneron Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Axiom Investors sold 77,772 Regeneron Pharmaceuticals shares in Q1 2016, an estimated $42.2M.
Axiom Investors first reported a position in Regeneron Pharmaceuticals in Q3 2014 and held it in 6 quarters.
Axiom Investors's Regeneron Pharmaceuticals position peaked at $52M in Q2 2015.
550 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Axiom Investors's 13F filing for Q1 2016, filed 12 May 2016.